Corrigendum to Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study Ann Rheum Dis. 2023;82:1404-1414
关于在未接受过生物制剂DMARD治疗的活动性银屑病关节炎患者中应用Bimekizumab治疗的更正:来自III期随机、安慰剂对照、活性参考BE OPTIMAL研究的52周疗效和安全性结果 Ann Rheum Dis. 2023;82:1404-1414
期刊:Annals of the Rheumatic Diseases
影响因子:20.6
doi:10.1016/j.ard.2025.05.013
Ritchlin, Christopher T; Coates, Laura C; McInnes, Iain B; Mease, Philip J; Merola, Joseph F; Tanaka, Yoshiya; Asahina, Akihiko; Gossec, Laure; Gottlieb, Alice B; Warren, Richard B; Ink, Barbara; Bajracharya, Rajan; Shende, Vishvesh; Coarse, Jason; Landewé, Robert B M